BenevolentAI
Joerg Moeller, MD, is a strategic executive with extensive experience in global research and development within the pharmaceutical industry. Currently serving as a Member of the Board of Directors at Secura Bio, Inc., Joerg previously held the position of Corporate EVP, Head of Global Research and Development at LEO Pharma. Joerg's tenure at Bayer spanned nearly two decades, where responsibilities included leading global research and development activities and overseeing significant product developments resulting in first-in-class approvals. Notable achievements include directing the clinical development of key drugs such as Rivaroxaban (Xarelto) and Aflibercept (Eylea). Joerg holds an MD from Ruhr University Bochum, alongside executive education credentials from IESE Business School and the Center for Creative Leadership.
This person is not in any teams
This person is not in any offices
BenevolentAI
8 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.